Efficacy classification of modern therapies in multiple sclerosis

Author:

Samjoo Imtiaz A1ORCID,Worthington Evelyn1ORCID,Drudge Christopher1ORCID,Zhao Melody1ORCID,Cameron Chris2ORCID,Häring Dieter A3,Stoneman Dee3,Klotz Luisa4,Adlard Nicholas3ORCID

Affiliation:

1. EVERSANA™, Burlington, ON, Canada

2. EVERSANA™, Sydney, NS, Canada

3. Novartis Pharma AG, Basel, Switzerland

4. Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany

Abstract

Background: The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. Materials & methods: Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate. Results: For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used. Conclusion: Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy.

Funder

Novartis

Publisher

Future Medicine Ltd

Subject

Health Policy

Reference60 articles.

1. Multiple sclerosis

2. Defining the clinical course of multiple sclerosis: The 2013 revisions

3. European Medicines Agency. Clinical investigation of medicinal products for the treatment of multiple sclerosis. (2015). https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-treatment-multiple-sclerosis

4. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

5. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3